Company Overview
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. The ANAVEX 2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The company's ANAVEX 3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a clinical stage drug candidate demonstrating disease-modifying activity against Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -78.83% |
| 6 Months: | -43.22% |
| 3 Months: | -21.86% |
| 1 Month: | -2.80% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)40.65 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 81.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AVXL Anavex Life Sciences Corp. R2K | 2.43 | -5.28 | $225.19M | 0.00% | -54.15% | -33.63% | - | - |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2013 | Dec 2013 | Mar 2014 | Jun 2014 | Dec 2014 | Mar 2015 | Jun 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 13.58M | 12.42M | 14.31M | 11.48M | 6.78M |
| Operating Income | -125.98K | -309.61K | -1.02M | -998.83K | -770.68K | -858.34K | -1.51M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -11.72M | -11.52M | -12.46M | -15.38M | -14.19M | -13.53M | -11.38M | -12.62M | -14.60M | - | -13.58M | -12.42M | -14.31M | -11.48M | -6.78M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -13.58M | -12.42M | -14.31M | -6.49M | -6.78M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -12.11M | -11.20M | -13.24M | -9.83M | -5.66M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -124.00K | 0 | - | - | - | 18.00K |
| Net Income | -151.92K | 358.64K | -1.02M | -1.01M | -786.72K | -1.72M | -4.24M | -3.95M | -2.03M | -2.24M | -3.15M | -1.55M | -3.61M | -4.06M | -4.75M | -2.85M | -6.92M | -7.25M | -6.52M | -6.59M | -7.24M | -6.49M | -7.86M | -8.16M | -10.18M | -10.88M | -10.44M | -12.37M | -12.97M | -13.11M | -11.28M | -8.62M | -10.55M | -12.21M | - | -12.11M | -11.20M | -13.24M | -9.83M | -5.68M |
| Diluted EPS | -0.01 | -0.01 | -0.03 | -0.03 | -0.06 | -0.12 | -0.22 | -0.12 | -0.06 | -0.06 | -0.08 | -0.04 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.17 | -0.17 | -0.14 | -0.11 | -0.13 | -0.14 | - | -0.14 | -0.13 | -0.16 | -0.11 | -0.06 |
| R&D Expense | 39.02K | 5.18K | 118.15K | 265.01K | 318.62K | 407.15K | 799.46K | 1.16M | 1.09M | 1.16M | 2.04M | 2.49M | 2.30M | 2.69M | 3.25M | 3.00M | 5.71M | 6.08M | 5.76M | 6.35M | 6.05M | 6.73M | 7.93M | 6.72M | 8.96M | 8.66M | 8.60M | 9.27M | 12.07M | 11.31M | 10.28M | 8.68M | 9.73M | 11.81M | - | 10.45M | 9.89M | 9.96M | - | 4.66M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Sep 2005 | Sep 2006 | Sep 2007 | Sep 2008 | Sep 2009 | Sep 2010 | Sep 2011 | Sep 2012 | Sep 2013 | Sep 2014 | Sep 2015 | Sep 2016 | Sep 2017 | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 50.99M | 55.74M | 52.80M | 51.37M |
| Operating Income | - | - | - | - | - | -5.65M | -6.18M | -4.32M | -2.14M | -2.97M | - | - | - | - | - | -31.09M | - | -50.99M | -55.74M | -52.80M | -51.37M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -47.62M | -46.54M | -43.00M | -46.38M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 964.00K | 0 | 0 |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -47.62M | -47.51M | -43.00M | -46.38M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 268.00K | 358.00K | 7.00K | 0 | - |
| Net Income | -91.62K | -25.53K | -1.58M | -5.35M | -5.50M | -8.78M | -7.31M | -8.30M | -3.70M | -9.97M | -12.11M | -14.74M | -13.46M | -17.25M | -26.29M | -26.28M | - | -47.98M | -47.51M | -43.00M | -46.38M |
| Diluted EPS | - | - | - | - | - | -0.41 | -0.29 | -0.29 | -0.12 | -1.02 | -0.65 | -0.42 | - | - | - | - | - | -0.62 | -0.60 | -0.52 | -0.54 |
| R&D Expense | - | - | - | - | - | 2.73M | 2.60M | 2.65M | 263.85K | 732.39K | 2.27M | 7.25M | 10.67M | 13.34M | 22.26M | 25.23M | 32.98M | 37.92M | 43.72M | 41.84M | 37.59M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Sep 2004 | Sep 2005 | Sep 2006 | Sep 2007 | Sep 2008 | Sep 2009 | Sep 2010 | Sep 2011 | Sep 2012 | Sep 2013 | Sep 2014 | Sep 2015 | Sep 2016 | Sep 2017 | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | - | - | - | 329.85K | 203.04K | 13.15K | 393.45K | 7.35M | 15.47M | 9.50M | 27.84M | 26.21M | 25.33M | 34.54M | - | 152.71M | 154.39M | 135.57M | 103.81M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 152.71M | 154.39M | 135.57M | 103.81M |
| Cash & Equivalents | - | - | - | - | - | - | - | - | - | - | - | - | 9.19M | 27.44M | 22.93M | 22.19M | 29.25M | - | 149.16M | 151.02M | 132.19M | 102.58M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.19M | 2.71M | 2.45M | 809.00K |
| Total Liabilities | - | - | - | - | - | - | 3.29M | 1.35M | 2.89M | 2.86M | 7.16M | 2.66M | 3.19M | 3.58M | - | 5.04M | 7.31M | - | 10.21M | 12.53M | 15.30M | 8.95M |
| Current Liabilities | - | - | - | - | - | - | - | - | 2.89M | 1.95M | 1.44M | 2.66M | 3.19M | 3.58M | 3.88M | 5.04M | - | - | 10.21M | 12.53M | 15.30M | 8.95M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | 5.72M | 332 | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Equity | 25.61K | -26.02K | -15.51K | -462.50K | -2.29M | -3.86M | -2.96M | -1.14M | -2.88M | -2.46M | 192.63K | 12.81M | 6.31M | 25.88M | 22.32M | 20.29M | 27.24M | - | 142.49M | 141.85M | 120.26M | 94.87M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 77.94M | 82.07M | 84.80M | 86.67M |
Cash Flows (Annual)
Figures in USD.
| Metric | Sep 2010 | Sep 2011 | Sep 2012 | Sep 2013 | Sep 2014 | Sep 2015 | Sep 2016 | Sep 2017 | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -4.59M | -3.80M | -1.69M | -777.57K | -2.66M | -4.23M | -9.24M | -9.02M | -12.58M | -18.53M | -21.29M | - | -24.24M | -27.79M | -30.81M | -39.04M |
| Investing Cash Flow | -3.31K | 0 | 0 | 0 | -3.02K | - | - | - | - | - | - | - | - | - | - | - |
| Financing Cash Flow | 4.51M | 3.67M | 1.57M | 1.11M | 9.58M | 12.26M | 3.13M | 27.27M | 8.07M | 17.78M | 28.35M | - | 21.29M | 29.65M | 11.97M | 9.43M |
| Capital Expenditure | - | - | - | - | -3.02K | - | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | -2.66M | - | - | - | - | - | - | - | -24.24M | -27.79M | -30.81M | -39.04M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | -2.95M | 1.87M | -18.84M | -29.61M |
Ratios (Annual)
Figures in %.
| Metric | Sep 2005 | Sep 2006 | Sep 2007 | Sep 2008 | Sep 2009 | Sep 2010 | Sep 2011 | Sep 2012 | Sep 2013 | Sep 2014 | Sep 2015 | Sep 2016 | Sep 2017 | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| ROE % | 352.1% | 164.6% | 341.6% | 233.5% | 142.6% | 296.7% | 639.6% | 288.7% | 150.2% | -5,175.0% | -94.5% | -233.6% | -52.0% | -77.3% | -129.6% | -96.5% | - | -33.7% | -33.5% | -35.8% | -48.9% |
| ROCE % | - | - | - | - | - | - | - | 150.3% | 137.1% | -50.2% | - | - | - | - | - | - | - | -35.8% | -39.3% | -43.9% | -54.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 8.21% | 7.61M | $20.43M |
| 2 | State Street Corporation | 4.87% | 4.51M | $12.11M |
| 3 | Vanguard Capital Management LLC | 4.17% | 3.86M | $10.37M |
| 4 | Two Sigma Investments, LP | 3.50% | 3.25M | $8.72M |
| 5 | Geode Capital Management, LLC | 2.36% | 2.19M | $5.88M |
| 6 | Susquehanna International Group, LLP | 1.07% | 995.66K | $2.67M |
| 7 | Summit Financial, LLC | 1.01% | 940.46K | $2.53M |
| 8 | Bank of America Corporation | 0.93% | 863.15K | $2.32M |
| 9 | Goldman Sachs Group Inc | 0.87% | 804.43K | $2.16M |
| 10 | Vanguard Portfolio Management LLC | 0.85% | 783.15K | $2.10M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AVXL
Penny Stocks To Watch In May 2026
The market is up 1.8% over the last week and has climbed 28% over the past year, with earnings forecast to grow by 17% annually. Though the term 'penny stock' might sound like a relic of past trading days, these smaller or newer companies c…
Exploring High Growth Tech Stocks In The US Market May 2026
The United States market has shown robust performance, rising 1.3% over the last week and 28% over the past year, with earnings projected to grow by 17% annually. In this thriving environment, identifying high growth tech stocks involves lo…
Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification
NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system (CNS) disord…
CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus
Anavex appointed former clinical development executive Terrie Kellmeyer as interim CEO following the departure of longtime chief executive Christopher Missling, while also signaling a delay in its quarterly SEC filing. Key Investor Takeaway…
Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer
NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer’s disease, Parkinson’s di…
AMD downgraded, Airbnb upgraded: Wall Street's top analyst calls
AMD downgraded, Airbnb upgraded: Wall Street's top analyst calls
AVXL — Frequently Asked Questions
What is the current share price of Anavex Life Sciences Corp. (AVXL)?
As of 2026-07-14 21:23 PDT, Anavex Life Sciences Corp. (AVXL) trades at $2.43 on NasdaqGS. Its 52-week range is $2.35 to $13.41.
What is the market capitalisation of AVXL?
Anavex Life Sciences Corp. (AVXL) has a market capitalisation of $225.19M on NasdaqGS.
What is the P/E ratio of AVXL?
AVXL trades at a trailing price-to-earnings (P/E) ratio of -5.28. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 1.83.
What is the return on equity (ROE) of AVXL?
AVXL has a return on equity (ROE) of -33.63%. Its return on capital employed (ROCE) is -54.15%.
Is AVXL a good stock to buy?
This page provides a data-driven analysis of Anavex Life Sciences Corp. (AVXL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.